Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
58.75
-2.20 (-3.61%)
Sep 10, 2026, 11:44 AM HKT
Biocytogen Pharmaceuticals (Beijing) Employees
Biocytogen Pharmaceuticals (Beijing) had 1,922 employees as of June 30, 2026. The number of employees increased by 479 or 33.19% since the number was reported on December 31, 2025.
Employees
1,922
Change
479
Growth
33.19%
Revenue / Employee
1.02M HKD
Profits / Employee
220.02K HKD
Market Cap
56.25B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,922 | 479 | 33.19% |
| Dec 31, 2025 | 1,443 | 326 | 29.19% |
| Dec 31, 2024 | 1,117 | 51 | 4.78% |
| Dec 31, 2023 | 1,066 | -282 | -20.92% |
| Dec 31, 2022 | 1,348 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Akeso | 4,082 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
| Shanghai Junshi Biosciences | 3,055 |
| Sichuan Kelun-Biotech Biopharmaceutical | 2,300 |
Biocytogen Pharmaceuticals (Beijing) News
- 1 month ago - Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals - South China Morning Post
- 2 months ago - Court Clears Biocytogen's RenNano® in Landmark Patent Dispute Against Harbour - Business Upturn
- 7 months ago - Strengthening Translational Research in India: GVSAP and Biocytogen Expand Collaboration - Business Upturn
- 1 year ago - Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Financial Post
- 1 year ago - Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Business Upturn
- 1 year ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Financial Post
- 1 year ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
- 1 year ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn